329 Studies Now Enrolling
Menu
Displaying 1 - 4 of 4
Condition: Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
This purpose of this study is to test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare genitourinary cancers that have no standard treatment options. Eligible participants must have confirmed diagnosis of one of the following cancers: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the…
Condition: Cancer
Investigator: Andrea Califano, PhD
Status: Currently Recruiting
The purpose of this protocol is to describe the acquisition and analysis of tumor tissue samples, with the goal of identifying master regulator genes that may be targeted by existing FDA-approved drugs or late-stage experimental compounds, either individually or in combination. Should we be able to predict such therapeutic targets, drug screening will be…
Condition: Cancer
Investigator: Linda Wu, MD
Status: Currently Recruiting
The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR-positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE